For the quarter ending 2025-09-30, LYRA has $43,709K in assets. $48,037K in debts. $22,055K in cash and cash equivalents.
| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 22,055 | 29,784 | ||
| Prepaid expenses and other current assets | 964 | 1,279 | ||
| Total current assets | 23,019 | 31,063 | ||
| Total | 5,570 | - | ||
| Accumulated depreciation | 4,448 | - | ||
| Property and equipment, net | 1,122 | 1,159 | ||
| Operating lease right-of-use assets | 17,575 | 18,358 | ||
| Restricted cash | 1,993 | 1,993 | ||
| Total assets | 43,709 | 52,573 | ||
| Accounts payable | 627 | 680 | ||
| Restructuring liability | 3,059 | 3,486 | ||
| Accrued expenses and other current liabilities | 1,103 | 2,413 | ||
| Operating lease liabilities | 4,684 | 4,552 | ||
| Deferred revenue | 7 | 32 | ||
| Total current liabilities | 9,480 | 11,163 | ||
| Operating lease liabilities, net of current portion | 26,695 | 27,926 | ||
| Deferred revenue, net of current portion | 11,862 | 11,862 | ||
| Total liabilities | 48,037 | 50,951 | ||
| Common stock, 0.001 par value 200,000,000 shares authorized at september 30, 2025 and december 31, 2024 1,644,454 and 1,310,308 shares issued and outstanding as of september 30, 2025 and december 31, 2024, respectively | 2 | 2 | ||
| Additional paid-in capital | 422,428 | 422,394 | ||
| Accumulated deficit | -426,758 | -420,774 | ||
| Total stockholders' (deficit) equity | -4,328 | 1,622 | ||
| Total liabilities and stockholders' (deficit) equity | 43,709 | 52,573 | ||
Lyra Therapeutics, Inc. (LYRA)
Lyra Therapeutics, Inc. (LYRA)